{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:49:33Z","timestamp":1760402973355,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastrointestinal Disorders"],"abstract":"<jats:p>Background: the presence of liver metastasis in colorectal cancer (CRC) remains one of the most significant prognostic factors. Objective: systematically review the results of studies evaluating the benefit of adding bevacizumab to a normal chemotherapy regime in the survival of patients with colorectal-cancer liver metastasis (CRLM). Search methods: Pubmed and Google Scholar databases were searched for eligible articles (from inception up to the 2 April 2019). Inclusion criteria: studies including patients with CRLM receiving anti-vascular endothelial growth factor (VEGF; bevacizumab) as treatment, overall survival as an outcome; regarding language restrictions, only articles in English were accepted. Main results: Eleven studies met the inclusion criteria. In 73% of these cases, chemotherapy with bevacizumab was an effective treatment modality for treating CRLM, and its administration significantly extended both overall survival (OS) and\/or progression-free survival (PFS). Nevertheless, three articles showed no influence on survival rates of bevacizumab-associated chemotherapy. Author conclusions: It is necessary to standardize methodologies that aim to evaluate the impact of bevacizumab administration on the survival of patients with CRLM. Furthermore, follow-up time and the cause of a patient\u2019s death should be recorded, specified, and cleared in order to better calculate the survival rate and provide a comparison between the produced literature.<\/jats:p>","DOI":"10.3390\/gidisord2020007","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T03:23:06Z","timestamp":1587439386000},"page":"71-85","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coadjuvant Anti-VEGF A Therapy Improves Survival in Patients with Colorectal Cancer with Liver Metastasis: A Systematic Review"],"prefix":"10.3390","volume":"2","author":[{"given":"Isabel","family":"Novo","sequence":"first","affiliation":[{"name":"School of Medicine, University of Minho, 4710-070 Braga, Portugal"}]},{"given":"B\u00e1rbara","family":"Campos","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Minho, 4710-070 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7574-6489","authenticated-orcid":false,"given":"Filipa","family":"Pinto-Ribeiro","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Minho, 4710-070 Braga, Portugal"},{"name":"Life and Health Sciences Research Institute (ICVS)\/3B\u2019s - PT Government Associate Laboratory, 4710-070 Braga\/Guimar\u00e3es, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3526-3199","authenticated-orcid":false,"given":"Sandra F.","family":"Martins","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Minho, 4710-070 Braga, Portugal"},{"name":"Life and Health Sciences Research Institute (ICVS)\/3B\u2019s - PT Government Associate Laboratory, 4710-070 Braga\/Guimar\u00e3es, Portugal"},{"name":"Surgery Department, Coloproctology Unit, Braga Hospital, 4710-243 Braga, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Ilic, I., Jankovic, S., and Ilic, M. (2016). Bevacizumab combined with chemotherapy improves survival for patients with metastatic colorectal cancer: Evidence from meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161912"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, Y.C., Lee, Y.L., Chuang, J.P., and Lee, J.C. (2013). Differences in survival between colon and rectal cancer from SEER data. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078709"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/annonc\/mdq168","article-title":"Primary colon cancer: ESMO clinical practice guidelines for diagnosis, adjuvant treatment and follow-up","volume":"21","author":"Labianca","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_4","first-page":"1949","article-title":"Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer","volume":"36","author":"Umehara","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.10.009","article-title":"Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis","volume":"106","author":"Baraniskin","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_7","first-page":"1","article-title":"Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?","volume":"29","author":"Lambrechts","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","article-title":"Markers of Response for the Antiangiogenic Agent Bevacizumab","volume":"31","author":"Lambrechts","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s40262-016-0406-3","article-title":"Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients","volume":"55","author":"Caulet","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11523-015-0377-6","article-title":"Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort","volume":"11","author":"Rouyer","year":"2016","journal-title":"Target Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2010.32.5977","article-title":"Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer","volume":"29","author":"Kemeny","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1200\/JCO.2012.45.2854","article-title":"Optimal morphologic response to preoperative chemotherapy: An alternate outcome end point before resection of hepatic colorectal metastases","volume":"30","author":"Shindoh","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CAD.0000000000000290","article-title":"Target hepatic artery regional chemotherapy and Bevacizumab perfusion in liver metastatic Colorectal cancer after failure of first-line or second-line systemic chemotherapy","volume":"27","author":"Chen","year":"2016","journal-title":"Anticancer Drugs"},{"key":"ref_14","first-page":"6655","article-title":"Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study)","volume":"34","author":"Beppu","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00268-009-0251-8","article-title":"Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: Case-matched control study","volume":"34","author":"Mahfud","year":"2010","journal-title":"World J. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jso.23142","article-title":"Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases","volume":"106","author":"Marsman","year":"2012","journal-title":"J. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1245\/s10434-008-0190-x","article-title":"Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases","volume":"16","author":"Scoggins","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-year survival after resection of colorectal liver metastases defines cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/SLA.0b013e31822f4f88","article-title":"Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer","volume":"254","author":"House","year":"2011","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann. Surg."},{"key":"ref_21","unstructured":"Pearce-Smith, N. (2019, May 12). Critical Appraisal Skills Programme (CASP) Checklist: 10 Questions to Help You Make Sense of a Systematic Review. Available online: https:\/\/casp-uk.net\/wp-content\/uploads\/2018\/01\/CASP-Systematic-Review-Checklist_2018.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"CASP (2013). Critical appraisal skills programme. J. Pharmacol. Pharmacother., 4, 76.","DOI":"10.4103\/0976-500X.107697"},{"key":"ref_23","unstructured":"CASP (2019, May 12). Critical Appraisal Skills Programme: CASP Case Control Study Checklist. Available online: https:\/\/www.casp-uk.net."}],"container-title":["Gastrointestinal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2624-5647\/2\/2\/7\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:01Z","timestamp":1760364541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2624-5647\/2\/2\/7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["gidisord2020007"],"URL":"https:\/\/doi.org\/10.3390\/gidisord2020007","relation":{},"ISSN":["2624-5647"],"issn-type":[{"type":"electronic","value":"2624-5647"}],"subject":[],"published":{"date-parts":[[2020,4,18]]}}}